AACR21: Eli Lilly blazes new trail for RET inhibitor, ginning up a response in 9 solid tumor types in early data
Eli Lilly was first to market with its RET fusion-inhibitor Retevmo in May, staking its claim in the rare tumor indication. But Roche wasn’t far …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
